

Finnegan, Women's Health Initiative Program Office, 7550 Rockville Pike, Room 6A09, Bethesda, Maryland 20892-9110 or call non-toll-free number (301) 402-2900, or E-mail your request, including your address to: <FinnegaL@od31em1.od.nih.gov>.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before January 3, 1997.

Dated: October 23, 1996.

Stephen Benowitz,

Executive Officer, OD.

[FR Doc. 96-28273 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for B-Cell Lymphoma Tumor Specific Antigen Studies

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer and Advancement Act of 1995), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks a Cooperative Research and Development Agreement (CRADA) with a pharmaceutical or biotechnology company. A major goal of the CRADA is to develop strategies to isolate B-cell lymphoma tumor specific antigen. The CRADA would have an expected duration of one (1) to five (5) years. The goals of the CRADA include the rapid publication of research results and the timely commercialization of any products, diagnostics and treatments that result from the research.

ADDRESSES: Proposals and questions about this CRADA opportunity may be addressed to Gary Cuchural, Office of Technology Development, National Cancer Institute-Frederick Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702-1201, Telephone: (301) 846-5465, Facsimile: (301) 846-6820.

EFFECTIVE DATE: In view of the high interest in developing Anti-Cancer Vaccines in general, interested parties should notify the NCI Office of Technology Development in writing no later than December 4, 1996.

SUPPLEMENTARY INFORMATION: A major research goal of this CRADA is the

development of strategies for the isolation of lymphoma derived Ig protein, including for example, the molecular cloning of Ig variable regions for expression in eukaryotic and prokaryotic cells. Another major research goal of this CRADA is the development and implementation of procedures for the GMP production of Ig protein. GMP Ig protein will be produced in sufficient quantities to support vaccine formulation studies. Vaccine formulation studies with one of several carriers, final vaccine production, and/or testing may also be among the research goals of this CRADA.

The role of the National Cancer Institute in this CRADA will include, but not be limited to:

1. Providing intellectual, scientific, and clinical expertise and experience to the research project.
2. Planning and conducting research studies and interpreting research results.
3. Publishing research results.

The role of the CRADA Collaborator may include, but not be limited to:

1. Providing intellectual, scientific, and regulatory expertise and experience to the research project.
2. Planning and conducting research studies and interpreting research results.
3. Providing support for CRADA-related research. Such support may include personnel and/or financial support to facilities scientific goals. Such support should include the availability of GMP manufacturing facilities for this effort, such support should also include assuming the cost of production of GMP Ig protein in sufficient quantities to support vaccine formulation studies. If vaccine formulation studies with one of several carriers, final vaccine production and/or testing are among the research goals of this CRADA, such support should also include assuming the cost of production of GMP vaccines in sufficient quantities to support these goals.
4. The experience and financial ability to support an IND.
5. Publishing research results.

Selection criteria for choosing the CRADA Collaborator may include, but not be limited to:

1. The ability to collaborate with NCI on research and development of this technology. This ability can be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development.
2. The demonstration of adequate resources to perform the research,

development and commercialization of this technology (e.g. facilities, personnel and expertise) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator's proposal.

3. The willingness to commit best effort and demonstrated resources to the research, development and commercialization of this technology.

4. The demonstration of expertise in the commercial development, GMP production, marketing and sales of patient-specific products related to this area of technology.

5. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities.

6. The willingness to cooperate with the National Cancer Institute in the timely publication of research results.

7. The agreement to be bound by the appropriate DHHS regulations relating to human subjects, and all PHS policies relating to the use and care of laboratory animals.

8. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the equitable distribution of patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor, with (1) the grant of a non-exclusive license to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect and exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor.

Dated: October 24, 1996.

Thomas D. Mays,

Director, Office of Technology Development, National Cancer Institute, National Institutes of Health.

[FR Doc. 96-28275 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent applications referenced below may be obtained by

contacting Stephen Finley, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (telephone 301/496-7735, ext. 215; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent applications.

A Method for Imaging Nicotinic Acetylcholinergic Receptors in the Brain Using Radiolabeled Pyridyl 7-Azabicycloheptanes

ED London, AS Kimes, A Horti, RF Dannals, M Kassiou (NIDA) Serial No. 08/642,636 filed 06 May 96

The current invention embodies the use of radiolabeled analogs of epibatidine to noninvasively image and quantify levels of nicotinic acetylcholine receptors in a living mammalian brain, using Positron Emission Tomography or other nuclear medicine methods. As nicotinic acetylcholine receptors have been implicated in various neuropathological and physiological disorders, including Alzheimer's disease, the invention may represent a powerful new method for the noninvasive diagnosis of Alzheimer's disease and other disorders. In addition, the method embodied in the invention may prove valuable for use in monitoring the progression of various disorders and in determining the efficacy of drug therapy protocols used in the treatment of these disorders. (portfolio: Central Nervous System—Diagnostics, in vivo)

Identification of an Allelic Ser₈₅₇-Asn₈₅₇ Variation of the Human Delayed Rectifier Potassium Channel DRK1 (KCNB1 locus)

D Goldman, AW Bergen, CM Mazzanti, S Michelini (NIAAA) Serial No. 60/020,348 filed 24 Jun 96

The DRK1 potassium channel is voltage sensitive such that as phosphorylation of the protein is increased the current is reduced, thereby increasing the cell's excitability. The amino- and carboxyl-terminal regions of DRK1 are located in the cytoplasm. A new, but naturally occurring substitution of the human delayed rectifier potassium channel DRK1 (KCNB1 locus) was mapped to chromosome 20q13.2. The nonconservative substitution occurs at position 857 in the carboxy terminal region of the protein. Transmembrane sequences of the rat and human DRK1 have been shown elsewhere to be identical, but have different pharmacological and conductance differences. The substitution of

cytoplasmic serine to asparagine may effectively remove a possible phosphorylation site which could result in increased excitability of the cell or effect the function of the protein by altering the conformation, thereby accounting for the pharmacological and conductance changes. The DRK1 was mapped to the same locus as the dominantly inherited EEG trait difference, a low voltage alpha trait difference (20q13.3-13.3), but no correlation could be found between the substitution and the low voltage alpha trait. (portfolios: Central Nervous System—Therapeutics, psychotherapeutics; Central Nervous System—Diagnostics; Central Nervous System—Research Materials).

Dated: October 28, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-28274 Filed 11-1-96; 8:45 am]
BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Clinical Trials Review Working Group, November 25-26, 1996 at the Doubletree Hotel, Rockville, Maryland.

The meeting will be open to the public on November 25, 1996 from 8 am to 2 pm for discussions of methods to maximize the exchange of information and collaboration between laboratory and clinical scientists and between the pharmaceutical industry and NCI funded researchers, and on November 26 from 8 am to 8:30 am for introductory remarks and welcome.

The meeting will be closed to the public on November 25, 1996 from 2 pm to approximately 6 pm and on November 26 from 8:30 am to approximately 6 pm for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the Clinical Trials Extramural Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. John S. Cole, III, Executive Secretary, National Cancer

Institute Clinical Trials Review Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892 (301-496-1718).

Individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. Cole in advance of the meeting.

Dated: October 28, 1996.

Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-28266 Filed 11-1-96; 8:45 am]
BILLING CODE 4101-01-M

National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Frederick Cancer Research and Development Center Advisory Committee.

The open portion of the meeting will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Committee Name: Frederick Cancer Research and Development Center Advisory Committee.

Date: December 17-18, 1996.

Place: Frederick Cancer Research and Development Center, Building 549, Executive Board Room.

Open: December 17-8:30 a.m.-11:00 a.m.

Agenda: Discussion of administrative matters such as future meetings, budget, and information items related to the operation of the NCI Frederick Cancer Research and Development Center.

Closed: December 17-11 a.m. to 5:00 p.m. December 18-8:30 a.m. to 5:00 p.m.

Agenda/Purpose: Discussion of previous site visit report and response for the Core Support Services with Science Applications International Corporation. The majority of the closed session will be devoted to a site review of the Molecular Virology and Carcinogenesis Laboratory under contract with ABL-Basic Research.

Contact Person: Cedric W. Long, Ph.D., Frederic Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702, Telephone: 301-846-1108.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(2)(4) and 552b(c)(6), Title 5 U.S.C. The report and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the programs, disclosure of